Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
modakafusp alfa + carfilzomib
- Development stage
- Unknown
- Lead developer
- Takeda
- Modality
- Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Cytokines & Interferons → Recombinant Proteins and Enzymes
- Administration
- Intravenous
01
Overview
This is a combination therapy of **modakafusp alfa** (previously TAK-573) and **carfilzomib** being investigated for the treatment of relapsed/refractory multiple myeloma. **Modakafusp alfa** is a first-in-class immunocytokine fusion protein consisting of two attenuated interferon alfa-2b molecules fused to a humanized anti-CD38 IgG4 monoclonal antibody. It specifically targets CD38-expressing myeloma cells, delivering interferon-alpha directly, inducing tumor cell death through anti-proliferative and pro-apoptotic signals and immune activation. **Carfilzomib** is a second-generation selective proteasome inhibitor; it inhibits the chymotrypsin-like activity of the 20S proteasome, leading to apoptosis of myeloma cells. The combination aims to leverage immune-targeted cytokine delivery and proteasome inhibition for synergistic anti-myeloma effects. The combination is currently being evaluated primarily in patients with relapsed/refractory multiple myeloma.
- Brand names
- None
- Other names
- modakafusp alfa + carfilzomib
02
Targets
PSMB7 (Proteasome subunit beta type-7)CD38 (Cluster of Differentiation 38)IFNAR (Immune system modulation via type I interferon receptor)PSMB5 (Proteasome subunit beta Type-5)
Beyond the preview
Go deeper on modakafusp alfa + carfilzomib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on modakafusp alfa + carfilzomib.